Stock 6589 EIRGENIX INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News EirGenix Inc.

Equities

6589

TW0006589005

End-of-day quote Taipei Exchange
Other stock markets
 03:30:00 04/06/2024 am IST 		5-day change 1st Jan Change
79.3 TWD -0.25% Intraday chart for EirGenix Inc. -1.00% -21.09%
15/05 EirGenix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
22/03 EirGenix Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
EirGenix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
EirGenix Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
EirGenix, Inc. Resolves to Sign the Contract with Clinical CRO and the Relevant Companies for Phase III Clinical Trail of the EG1206A
CI
EirGenix Inc.'s Breast Cancer Biosimilar Receives Marketing Authorization by EC
CI
EirGenix Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
EirGenix Inc. Announces the Establishment of Phase II Facility and Production Equipment in Zhubei
CI
Novartis' Sandoz Unit Says European Medicines Agency Panel Supports Approval of Trastuzumab Biosimilar
MT
Novartis Cancer Drug Gets Marketing Recommendation from European Medicines Agency
DJ
Novartis Unit Wins European Medicines Agency's Positive Opinion for Breast Cancer Biosimilar
MT
National Health Insurance Administration Approves EirGenix Inc.'S Biosimilar, Eirgasun Vial 150 Mg to Be Enrolled in the Reimbursement System
CI
EirGenix Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
EirGenix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
EirGenix Inc. Completes the Phase 1 Clinical Trial of Its Second Breast Cancer Biosimilar EG1206A in Europe
CI
EirGenix Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
EirGenix Inc. announced a financing transaction
CI
EirGenix Inc. Announces Executive Changes
CI
Eirgenix Inc. Announces Establishment of Corporate Governance Committee
CI
EirGenix Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
Eirgenix, Inc., Submits the Biosimilar Drug Eirgasum of 150 Mg Powder for Concentratefor Solution for Infusion Presentation New Drug Application to the Taiwan Food and Drug Administration
CI
EirGenix Inc. Appoints Po-Chih Chen as Remuneration Committee
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 6589 Stock
  4. News EirGenix Inc.